| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
IL-17A 8.2 (pIC50)
Interleukin-17A (IL-17A), a pro-inflammatory cytokine produced primarily by Th17 cells. IL-17A is implicated in the pathogenesis of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis), cancer (tumor promotion or suppression depending on context), and neurodegenerative disorders. |
|---|---|
| ln Vitro |
A biochemical or cell-based assay measured a pIC50 of 8.2 for IL-17A modulator-1, which corresponds to an IC50 of approximately 6.3 nM. It inhibits the biological action of IL-17A, presumably by blocking IL-17A binding to its receptor or by inhibiting downstream signaling.
|
| ln Vivo |
No published in vivo data. Based on its potent in vitro activity (pIC50 = 8.2), IL-17A modulator-1 would be expected to reduce IL-17A-mediated inflammation in vivo, such as attenuating skin inflammation in psoriasis models or reducing joint swelling in arthritis models, though this remains to be validated.
|
| Enzyme Assay |
Binding affinity for IL-17A is assessed via a biochemical assay (e.g., AlphaLISA or TR-FRET). Recombinant human IL-17A and a labeled IL-17A antibody or receptor are incubated with serially diluted modulator-1 (0.001-10 uM). The assay signal is measured to calculate the half-maximal inhibitory concentration (pIC50 = 8.2).
|
| Cell Assay |
For in vitro cellular assays, IL-17A-responsive cells (e.g., HT-29 or human dermal fibroblasts) are seeded in 96-well plates. Cells are pre-incubated with serially diluted IL-17A modulator-1 (0.1-1000 nM) for 1 hour, then stimulated with recombinant human IL-17A (10 ng/mL) for 24 hours. Supernatants are collected, and CXCL8 (IL-8) or CCL20 levels are measured by ELISA. The IC50 is calculated from the dose-response curve.
|
| Animal Protocol |
No published in vivo data. For research use, the imiquimod (IMQ)-induced psoriasis-like mouse model is used. BALB/c mice are treated topically with IMQ cream on the shaved back for 5-7 days. IL-17A modulator-1 is administered orally or intraperitoneally at 10-50 mg/kg daily. PASI scores (erythema, scaling, thickness) are recorded daily. On day 5-7, skin biopsies are taken for histopathological analysis and cytokine measurement by qPCR or ELISA.
|
| ADME/Pharmacokinetics |
IL-17A modulator-1 has a molecular weight of 561.63 g/mol and a formula of C33H31N5O4. DMSO solubility is high. Detailed PK parameters (e.g., half-life, oral bioavailability) are not publicly available; as a small molecule, PK properties will depend on formulation and administration route, with oral bioavailability likely moderate.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data are not publicly available. As a small-molecule IL-17A modulator, potential toxicities may include increased susceptibility to infections (consistent with IL-17A blockade) and gastrointestinal disturbances. No severe toxicities have been reported in research models.
|
| References | |
| Additional Infomation |
IL-17A modulator-1 is a research compound not approved for clinical use. It is extracted from patent WO2021239743+A1 (example 9). It is used to study the role of IL-17A in autoimmune diseases, cancer, and neurodegenerative disorders. It is a tool compound for investigating the therapeutic potential of small-molecule IL-17A modulation.
|
| Molecular Formula |
C33H31N5O4
|
|---|---|
| Molecular Weight |
561.63
|
| Exact Mass |
561.237
|
| CAS # |
2748749-29-1
|
| Related CAS # |
IL-17A modulator-2;2748749-47-3
|
| PubChem CID |
162362218
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
42
|
| Complexity |
825
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(C1C=CC=CC=1)(C1C=CC=CC=1)[C@@H](C(=O)NC1C=CC(C2=C(C=NC=C2OC)OC)=CC=1)NC(C1N(N=CC=1)C)=O
|
| InChi Key |
CIIPUPSMHRZVPV-HKBQPEDESA-N
|
| InChi Code |
InChI=1S/C33H31N5O4/c1-38-26(18-19-35-38)32(39)37-31(29(22-10-6-4-7-11-22)23-12-8-5-9-13-23)33(40)36-25-16-14-24(15-17-25)30-27(41-2)20-34-21-28(30)42-3/h4-21,29,31H,1-3H3,(H,36,40)(H,37,39)/t31-/m0/s1
|
| Chemical Name |
N-[(2S)-1-[4-(3,5-dimethoxypyridin-4-yl)anilino]-1-oxo-3,3-diphenylpropan-2-yl]-2-methylpyrazole-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (178.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (4.45 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7805 mL | 8.9027 mL | 17.8053 mL | |
| 5 mM | 0.3561 mL | 1.7805 mL | 3.5611 mL | |
| 10 mM | 0.1781 mL | 0.8903 mL | 1.7805 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
